OT

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%
HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$50.00M
EPS-0.5200
P/E Ratio-2.73
Earnings Date03/30/2026

ostx

Net Interest Income

Last Annual Value

-2.05M

3-Year CAGR

7%

5-Year CAGR

65%

10-Year CAGR

41%

OT

OS Therapies Incorporated Competitors Analysis of Net Interest Income

OSTX · NYSE
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
-2.05M
N/AN/AN/A 
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
1.94M
106.7%69.7%N/A
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
1.30M
-10.8%55.5%N/A
2.16M
20.3%75.0%N/A
450.00K
-31.8%57.9%N/A
125.64K
N/AN/AN/A
-2.17M
N/AN/AN/A
-90.00K
N/AN/AN/A
-525.88K
N/AN/AN/A
-659.00K
N/AN/AN/A
0.00
N/AN/AN/A
OT

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

Intrinsic Value
Current Price: $1.42